Martlet Capital
VC Fund
Cambridge, United Kingdom
Martlet Capital is an early-stage investor based in Cambridge, providing patient capital to deep technology and life science startups with high growth potential. They seek to support entrepreneurs with value beyond capital. They have experience of helping companies scale from first-round through to exit. Visit their website to take a look at how we work and their investment focus.
- Total investments:
- 55
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Martlet Capital invests in
Stages Martlet Capital invests in
Countries Martlet Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $642k–$7.5M
- Pre-Seed
- $193k–$1.2M
- Series A
- $1M–$9.5M
Investment Focus
Industry
- Health Care 9 (16%)
- Biotechnology 9 (16%)
- Software 8 (15%)
- Medical 5 (9%)
- Sensor 4 (7%)
Stage
- Seed 30 (55%)
- Series A 10 (18%)
- Pre-Seed 4 (7%)
- Series B 3 (5%)
- Angel 2 (4%)
Country
- United Kingdom 41 (75%)
- United States 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alan Cowley
Investment Analyst
|
Investment Analyst | Total investments: 0 | Find email | |
Robert Marshall
Founder, Chief Executive Officer & Executive Chairman
|
Founder, Chief Executive Officer & Executive Chairman | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AllFocal Optics revolutionizes display technology through groundbreaking nanophotonic solutions. | $3.6M / Seed / Nov 06, 2024 | ||
| Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives | $16M / Seed / Apr 30, 2024 | ||
| Xampla creates plant protein material for commercial use. Our next generation material performs like synthetic polymers, but decomposes naturally and fully, without harming the environment. | $7.2M / Series B / Jan 30, 2024 | ||
| Xampla creates plant protein material for commercial use. Our next generation material performs like synthetic polymers, but decomposes naturally and fully, without harming the environment. | $7M / Venture - Series Unknown / Jan 30, 2024 | ||
| OctaiPipe is a Federated Learning Operations (FL-Ops) architecture developed exclusively for Edge AIoT devices. It simplifies the entire lifecycle, from setup and training to smooth deployment, fine-tuning, and continuous learning. This allows data scientists to develop distributed IoT solutions that can learn and adapt at scale while lowering thecost of monitoring, maintenance, upgrades, and auditing. | $3.9M / Seed / Jan 23, 2024 | ||
| Spotta is the creator of an ultra-low-power insect monitoring sensor for detecting bed bug infestations. The company's sensor is battery-powered, allowing users to be notified whenever bed bugs are detected and analyzing the detection to ensure users are only notified about genuine incidents, allowing customers to prevent bed bugs fromentering the room and make treatment easier and less expensive. | $3.8M / Series A / Dec 15, 2023 | ||
| Nu Quantum is a telecommunications company that develops end-to-end quantum cryptography systems.It secures communications within and between cities through urban and satellite free-space optical links. The system helps with the realization of commercial deliverable photonic technologies by combining novel materials and semiconductor technology.This enables clients to secure the exchange of cryptographic keys for the ultra-sensitive detection of light.Yuri Andersson, Mete Atatüre, and Carmen Berraquero founded Nu Quantum in Cambridge, Cambridgeshire in 2018. | $8.5M / Seed / Nov 02, 2023 | ||
|
Strolll
|
Strolll Neurotechnology | $2.6M / Seed / Oct 17, 2023 | |
| Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available. | $7.3M / Seed / Sep 28, 2023 | ||
| VC-backed startup developing software solutions and tools for building and validating AI-based perception. The company's vision is to accelerate the deployment of affordable autonomy solutions for automotive and industrial applications. | $2M / Seed / Jun 29, 2023 | ||
| See all 55 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Martlet Capital invest in?
Martlet Capital invests primarily in Health Care, Biotechnology and Software startups, most often at Seed and Series A stage. Most of the 55 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Martlet Capital invest in?
Martlet Capital typically joins rounds of $642k–$7.5M at Seed, $193k–$1.2M at Pre-Seed and $1M–$9.5M at Series A. These are whole funding-round sizes, not Martlet Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Martlet Capital took part in.
How do I contact Martlet Capital?
Public channels for Martlet Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Martlet Capital?
The team at Martlet Capital includes Alan Cowley (Investment Analyst) and Robert Marshall (Founder, Chief Executive Officer & Executive Chairman). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
